HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 05 & 06, May & June 2022 – Living Better for Longer: Cutting-Edge Research in Geriatric Medicine       » How Oxidation Can Lead to Mitochondrial Dysfunction and Age-Dependent Cognitive Disorders       » New Semiconductor Microchip Detects Prostate Cancer Markers With Ultra-High Sensitivity       » New Method for Synthesising Sulphur-Based Medicines Can Boost Drug Discovery Efficiency and Speed       » Selecting the Best Target for Deep Brain Stimulation in Parkinson’s Disease       » A Single Metabolite Can Promote Tissue Regeneration and Delay Ageing       » A New Light-Sensitive Way to Control Parathyroid Hormone Secretion for the Prevention of Bone Loss      
NEWS CRUNCH
Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam. The country received high-tech product for treatment of certain types of blood cancer. This was the first shipment under the 5-year contract with a local distributor. Previously, the Vietnamese patients could count only on the original products by Swiss global healthcare company F. Hoffmann-La Roche, but at a much higher price.

"Success of Russia's biosimilar rituximab has several ingredients. The product's high quality was proven in sizeable multinational clinical trials, yet its price is much lower than the originator's. This opened new opportunities to supply biosimilar rituximab to the patients who knew that the original product had been prohibitively expensive for them." Says BIOCAD's founder and CEO, Mr. Dmitri Morozov.

By now, BIOCAD has already signed more than a dozen agreements with the distribution and manufacturing companies in several countries of South-East Asia, such as the Philippines, Malaysia, Indonesia, and Thailand. Advanced Russian biotech products that are used for therapy of oncological and autoimmune diseases are in high demand WW. They are no inferior to the original products made by the leading Western companies, yet cost significantly less.

Source: BIOCAD
NEWS CRUNCH  
news Medtec China 2022 Is Now Open for Visitor Registration, Helping Medical Device Manufacturers in Medtech Sourcing and Supply Chain Stabilisation
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy